Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563200 | 0.86 | PDCD1 (0.46) | PDCD1CD274DPP4KMT2AFOLH1 | |
| SCHEMBL4630656 | 0.83 | PDCD1 (0.43) | PDCD1CD274DPP4KMT2AFOLH1 | |
| SCHEMBL3561165 | 0.83 | GABRA1 (0.44) | PDCD1CD274GABRA1GABRB2CYP2D6 | |
| SCHEMBL31261742 | 0.82 | DPP4 (0.60) | PDCD1CD274DPP4KMT2AFOLH1 | |
| SCHEMBL328862 | 0.82 | DPP4 (0.60) | PDCD1CD274DPP4KMT2AFOLH1 | |
| SCHEMBL4630157 | 0.82 | NR1H2 (0.48) | PDCD1CD274PTGS2PPARGPPARA | |
| SCHEMBL1241629 | 0.81 | KMT2A (0.47) | PDCD1CD274DPP4KMT2AFOLH1 | |
| SCHEMBL4630263 | 0.81 | NR1H2 (0.50) | PPARGPPARABCL2L1 | |
| Ethane SCHEMBL3681665 | 0.80 | DPP4 (0.58) | PDCD1CD274DPP4KMT2AFOLH1 | |
| Water SCHEMBL9719797 | 0.80 | DPP4 (0.58) | PDCD1CD274DPP4KMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-7659276-B2 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090143405-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7514438-B2 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143405-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | MCHR1, MC1R, NPY1R | PDCD1 4164/4885CD274 3620/4885DPP4 2629/4885 |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | MCHR1, MC1R, NPY1R | PDCD1 4164/4885CD274 3620/4885DPP4 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.